Coeptis Therapeutics (NASDAQ:ZSQR) Shares Up 8.9% – Should You Buy?

Shares of Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR) rose 8.9% during trading on Wednesday . The company traded as high as $11.52 and last traded at $11.52. 136,898 shares traded hands during mid-day trading, a decline of 31% from the average session volume of 197,687 shares. The stock had previously closed at $10.58.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen cut Coeptis Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has an average rating of “Sell”.

Coeptis Therapeutics Stock Up 6.5%

The firm has a market cap of $579.62 million, a P/E ratio of -4.47 and a beta of -0.22. The firm’s fifty day moving average is $12.24 and its 200 day moving average is $12.68. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.25 and a current ratio of 3.25.

Coeptis Therapeutics (NASDAQ:ZSQR) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.65) earnings per share for the quarter. The company had revenue of $0.11 million during the quarter. Coeptis Therapeutics had a negative net margin of 810.04% and a negative return on equity of 92.29%.

Hedge Funds Weigh In On Coeptis Therapeutics

A number of large investors have recently made changes to their positions in the company. Yorkville Advisors Global LP acquired a new stake in Coeptis Therapeutics during the 3rd quarter worth approximately $140,000. Geode Capital Management LLC boosted its stake in Coeptis Therapeutics by 12.6% in the 4th quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock valued at $600,000 after purchasing an additional 4,721 shares during the period. Steward Partners Investment Advisory LLC grew its holdings in Coeptis Therapeutics by 100.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock valued at $71,000 after buying an additional 2,500 shares in the last quarter. State Street Corp grew its holdings in Coeptis Therapeutics by 35.0% in the 4th quarter. State Street Corp now owns 26,830 shares of the company’s stock valued at $382,000 after buying an additional 6,962 shares in the last quarter. Finally, Marshall Wace LLP bought a new position in Coeptis Therapeutics during the 4th quarter worth $259,000. Institutional investors own 13.88% of the company’s stock.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.